How Governments Collaborated with Pfizer to Delivery the Vaccine

Vaccine Supply Chain

Critical challenges of the vaccine supply chain due to the COVID-19 pandemic had to do with cold storage, transportation, global distribution, and regulatory hurdles (Crommelin et al., 2021). Moderna and Pfizer both faced these challenges in scaling up and distributing their vaccines. This paper describes and discusses a few of them.

First, the Pfizer and Moderna vaccines required ultra-cold storage. Pfizer vaccine needed to be stored at about -70°C (-94°F), while Moderna's required -20°C (-4°F). These temperature conditions necessitated the use of specialized freezers and storage solutions. Since such infrastructure was not widely available, particularly in low-resource settings, it made distribution in some parts of the world very difficult (Crommelin et al., 2021).

This cold chain, however, had to be maintained throughout transportation. This meant using specialized containers filled with dry ice and equipped with real-time temperature monitoring. The transportation process had to be resilient enough to account for potential disruptions, too (Olutuase et al., 2022).

The global demand for COVID-19 vaccines was also immense, and this meant that both companies had to scale up production rapidly. There was thus an overwhelming demand for specific raw materials, such as the lipids used in the mRNA vaccine formulation, which actually faced potential shortages, and risked creating bottlenecks in the production process (Crommelin et al., 2021).

Distributing vaccines across countries was also a challenge. Wealthier nations were able to secure large quantities of vaccines early on. Plus, each country had its own regulatory framework and approval processes for vaccines. As a result, gaining emergency use authorization or full approval in multiple countries simultaneously became a hurdle to overcome for both companies (Crommelin et al., 2021).

There was also the challenge of having effective packaging, as this would impact the vaccine’s stability and efficacy. This involved using multi-dose vials, which had a limited window of use. The packaging also had to support the necessary cold chain conditions (Crommelin et al., 2021). On top of this, was the "last-mile" delivery, especially in low- and middle-income countries. In many places, infrastructures were lacking for this type of delivery (Olutuase et al., 2022).

There were also security concerns, supplier issues to consider, and how to coordinate a global response. The unprecedented demand and high value associated with the COVID-19 vaccines raised major security issues, as there a real risk of theft during transportation, and the potential for tampering during both transit and storage. Enhanced security measures and monitoring were needed throughout the supply chain.

Also a unique challenge in the vaccine supply chain management process was the specialized nature of certain components. Given the niche requirements of these components, only a handful of suppliers existed globally. This limited supplier base posed a risk: any disruption or setback with even one supplier could have cascading effects on the entire production process.

Thus, addressing the many different challenges was not easy. Pfizer and Moderna had to work closely with governments to manage it all and ensure global coordination at a truly international level. Governments, international organizations, the private sector, and civil society all acted as stakeholders, coming together to support the production and distribution of vaccines. This overall collective experience represented the critical support that both Pfizer and Moderna received and without which neither would have succeeded.